Phase I clinical study of peptide vaccine using novel tumor-associated antigen TTK against advanced esophageal carcinoma

Phase I clinical study of peptide vaccine using novel tumor-associated antigen TTK against advanced esophageal carcinoma - TTK peptide vaccine to advanced esophageal cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001014

Enrollment

Registered

2008-02-04

Start date

2008-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced esophageal cancer refractory to standard therapeutic modality

Interventions

Peptide vaccine therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance status 0-2 HLA-A24 positive Refractory to standard therapy (Chenorediotherapy)

Exclusion criteria

Exclusion criteria: Pregnancy Uncontrolled infection Uncontrolled brain metastasis

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Antitumor immune responses	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026